Larry Mathis Financial Planning LLC Makes New $1.01 Million Investment in Astrazeneca Plc $AZN

Larry Mathis Financial Planning LLC acquired a new stake in shares of Astrazeneca Plc (NYSE:AZN) during the fourth quarter, Holdings Channel reports. The firm acquired 5,770 shares of the company’s stock, valued at approximately $1,013,000. Astrazeneca accounts for approximately 0.9% of Larry Mathis Financial Planning LLC’s holdings, making the stock its 29th largest position.

A number of other hedge funds have also modified their holdings of AZN. Advisortrust Partners LLC acquired a new position in Astrazeneca during the fourth quarter worth $519,000. Hsbc Holdings PLC grew its holdings in shares of Astrazeneca by 0.4% in the 4th quarter. Hsbc Holdings PLC now owns 53,265 shares of the company’s stock worth $9,348,000 after purchasing an additional 208 shares during the last quarter. Mengis Capital Management Inc. increased its position in shares of Astrazeneca by 7.5% during the 4th quarter. Mengis Capital Management Inc. now owns 93,361 shares of the company’s stock worth $16,385,000 after purchasing an additional 6,519 shares in the last quarter. Pure Financial Advisors LLC lifted its holdings in Astrazeneca by 40.7% during the 4th quarter. Pure Financial Advisors LLC now owns 5,905 shares of the company’s stock valued at $1,036,000 after purchasing an additional 1,707 shares during the last quarter. Finally, Rehmann Capital Advisory Group boosted its position in Astrazeneca by 22.9% in the fourth quarter. Rehmann Capital Advisory Group now owns 13,924 shares of the company’s stock valued at $2,444,000 after buying an additional 2,594 shares in the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

AZN has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Astrazeneca in a research note on Tuesday, June 9th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a report on Tuesday, June 9th. Morgan Stanley reiterated an “overweight” rating on shares of Astrazeneca in a research report on Wednesday, April 8th. Sanford C. Bernstein reissued a “buy” rating on shares of Astrazeneca in a research note on Monday, May 4th. Finally, Wall Street Zen upgraded Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Twelve analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $205.33.

Astrazeneca Price Performance

AZN opened at $174.87 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. The stock has a market capitalization of $271.20 billion, a P/E ratio of 26.26, a price-to-earnings-growth ratio of 1.52 and a beta of 0.25. The company’s 50 day simple moving average is $186.62 and its 200-day simple moving average is $186.27. Astrazeneca Plc has a one year low of $137.23 and a one year high of $212.71.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The firm had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. Sell-side analysts anticipate that Astrazeneca Plc will post 9.39 earnings per share for the current fiscal year.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.